Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jun 04, 2014 4:27pm
203 Views
Post# 22630826

RE:RE:RE:RE:Third Party ASSURE

RE:RE:RE:RE:Third Party ASSUREThanks GV.

So it's good to know that the final post hoc finding has been verified by independent scientists as Don had indicated would happen in his February presentation. So that means that all post hoc findings have been independently verified and that is very good news.

I too believe they will move forward with the rvx-208 trial. KD won't let this be abandoned, at least at this stage. Afterall, with all of the very positive science what's is a few more million to bring this compound to market because the upside is enormous and sustained over years of payback relative to the risk.

From my perspective the stock is grossly undervalued but I'm glad to see it above $.70. It won't kick up until we get information. Investing in a communication vacuum definitely is suppressing the stock price.

My hypothesis remains that they are not communicating because they are well in to locking up a major agreement, IMO.

Let's keep hoping!!!
Cheers
Toinv
Bullboard Posts